Glucose conjugation for the specific targeting and treatment of cancer

Emilia C. Calvaresi, Paul J. Hergenrother

Research output: Contribution to journalArticle

Abstract

Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

Original languageEnglish (US)
Pages (from-to)2319-2333
Number of pages15
JournalChemical Science
Volume4
Issue number6
DOIs
StatePublished - May 7 2013

Fingerprint

Glycoconjugates
Glucose
Sugars
Facilitative Glucose Transport Proteins
Cytotoxins
Metabolism
Substrates
Pharmaceutical Preparations
Glycolysis

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Glucose conjugation for the specific targeting and treatment of cancer. / Calvaresi, Emilia C.; Hergenrother, Paul J.

In: Chemical Science, Vol. 4, No. 6, 07.05.2013, p. 2319-2333.

Research output: Contribution to journalArticle

@article{9e3a6fa84bef4be699b6bb8e7859766b,
title = "Glucose conjugation for the specific targeting and treatment of cancer",
abstract = "Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.",
author = "Calvaresi, {Emilia C.} and Hergenrother, {Paul J.}",
year = "2013",
month = "5",
day = "7",
doi = "10.1039/c3sc22205e",
language = "English (US)",
volume = "4",
pages = "2319--2333",
journal = "Chemical Science",
issn = "2041-6520",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - Glucose conjugation for the specific targeting and treatment of cancer

AU - Calvaresi, Emilia C.

AU - Hergenrother, Paul J.

PY - 2013/5/7

Y1 - 2013/5/7

N2 - Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

AB - Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

UR - http://www.scopus.com/inward/record.url?scp=84877724593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877724593&partnerID=8YFLogxK

U2 - 10.1039/c3sc22205e

DO - 10.1039/c3sc22205e

M3 - Article

AN - SCOPUS:84877724593

VL - 4

SP - 2319

EP - 2333

JO - Chemical Science

JF - Chemical Science

SN - 2041-6520

IS - 6

ER -